IL6 and neoplasm: LRRC4 binds to phosphotyrosine-dependent protein kinase 1 (PDPK1), promotes NF-κB activation in glioblastoma cells and secretion of Interleukin 6 (IL-6), C-C Motif Chemokine Ligand 2 (CCL2) and Interferon-gamma (IFN-γ), thereby inhibiting the expansion of tumor-infiltrating regulatory T cells and the growth of glioblastoma cells [31].